{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:33:28Z","timestamp":1794864808251,"version":"4.9.1"},"reference-count":12,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"3","license":[{"start":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2024.286002","type":"journal-article","created":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T03:35:24Z","timestamp":1729136124000},"page":"768-771","source":"Crossref","is-referenced-by-count":2,"title":["Frequency of secondary T-cell lymphoma in chimeric antigen receptor T-cell na\u00efve B-cell lymphoid-lineage cancers is higher than that reported on chimeric antigen receptor T-cell therapy"],"prefix":"10.3324","volume":"110","author":[{"given":"Christian","family":"Brieghel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren L.","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter de N.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten U.","family":"Niemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,10,17]]},"reference":[{"key":"73479","doi-asserted-by":"crossref","unstructured":"San-Miguel J, Dhakal B, Yong K. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023; 389(4):335-347.","DOI":"10.1056\/NEJMoa2303379"},{"key":"73480","doi-asserted-by":"crossref","unstructured":"Westin JR, Oluwole OO, Kersten MJ. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N Engl J Med. 2023; 389(2):148-157.","DOI":"10.1056\/NEJMoa2301665"},{"key":"73481","doi-asserted-by":"crossref","unstructured":"Coombs CC, Easaw S, Grover NS, O\u2019Brien SM. Cellular therapies in chronic lymphocytic leukemia and Richter\u2019s transformation: recent developments in chimeric antigen receptor T-cells, natural killer cells, and allogeneic stem cell transplant. Cancers (Basel). 2023; 15(6):1838.","DOI":"10.3390\/cancers15061838"},{"key":"73482","doi-asserted-by":"crossref","unstructured":"Verdun N, Marks P. Secondary cancers after chimeric antigen receptor T-cell therapy. N Engl J Med. 2024; 390(7):584-586.","DOI":"10.1056\/NEJMp2400209"},{"key":"73483","doi-asserted-by":"crossref","unstructured":"Hamilton MP, Sugio T, Noordenbos T. Risk of second tumors and T-cell lymphoma after CAR T-cell therapy. N Engl J Med. 2024; 390(22):2047-2060.","DOI":"10.1056\/NEJMoa2401361"},{"key":"73484","doi-asserted-by":"crossref","unstructured":"Elsallab M, Ellithi M, Lunning MA. Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System. Blood. 2024; 143(20):2099-2105.","DOI":"10.1182\/blood.2024024166"},{"key":"73485","doi-asserted-by":"crossref","unstructured":"Ghilardi G, Fraietta JA, Gerson JN. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nat Med. 2024; 30(4):984-989.","DOI":"10.1038\/s41591-024-02826-w"},{"key":"73486","doi-asserted-by":"crossref","unstructured":"Brieghel C, Werling M, Frederiksen CM. The Danish Lymphoid Cancer Research data resource: the basis for developing datadriven hematology. medRxiv. 2024.","DOI":"10.1101\/2024.04.11.24305663"},{"key":"73487","doi-asserted-by":"crossref","unstructured":"da Cunha-Bang C, Rostgaard K, Andersen MA. Risk of new malignancies among patients with CLL treated with chemotherapy: results of a Danish population-based study. Br J Haematol. 2021; 193(2):339-345.","DOI":"10.1111\/bjh.17337"},{"key":"73488","doi-asserted-by":"crossref","unstructured":"Arboe B, Olsen MH, G\u00f8rl\u00f8v JS. Treatment intensity and survival in patients with relapsed or refractory diffuse large B-cell lymphoma in Denmark: a real-life population-based study. Clin Epidemiol. 2019; 11:207-216.","DOI":"10.2147\/CLEP.S178003"},{"key":"73489","doi-asserted-by":"crossref","unstructured":"Lamble AJ, Schultz LM, Nguyen K. Risk of T-cell malignancy following CAR T cells in children, adolescents and young adults. Blood Adv. 2024; 8(13):3544-3548.","DOI":"10.1182\/bloodadvances.2024013243"},{"key":"73490","doi-asserted-by":"crossref","unstructured":"Kyvsgaard ER, Riley C, Clausen MR. Low mortality from COVID-19 infection in patients with B-cell lymphoma after bispecific CD20xCD3 therapy. Br J Haematol. 2024; 204(1):356-360.","DOI":"10.1111\/bjh.19156"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.286002\/77625","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.286002\/78133","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11789\/77625","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:07:28Z","timestamp":1794046048000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2024.286002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,17]]},"references-count":12,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.286002","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,17]]}}}